Synthesis of Epigenetic Regulator I-BET762 (GSK525762)

**Significance:** I-BET762 (GSK525762) has entered phase I/II clinical trials for the treatment of the aggressive NUT midline carcinoma and other cancers. It disrupts the function of the bromodomain and extra-terminal domain (BET) family of proteins. The synthesis depicted features the construction of the 1,4-benzodiazepine skeleton with incorporation of an (S)-aspartic acid moiety.

**Comment:** For a synthesis of benzophenone A, see: C.-w. Chung et al. *J. Med. Chem.* 2011, 54, 3827. The easy epimerization of the stereogenic center that occurs in the thionation reaction \( B \rightarrow C \) was suppressed by conducting the reaction in the presence of sodium carbonate. The \((R)\)-enantiomer is biologically inactive as a BET inhibitor.